Cerebras is seeking to go public at a valuation of about $8 billion. There are several red flags why I won't invest in its ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

Biohaven has surged driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies.

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...

Victoria’s Secret and the Unraveling of an American icon, authors Lauren Sherman and Chantal Fernandez weave together the ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...

PARIS (Reuters) -Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S.

Traders around the word awaited U.S. inflation data for September—and the implications it will have for rate cuts at the ...

ShareUK pharmaceutical giant, GSK said it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...